Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy - Trial NCT06061263
Access comprehensive clinical trial information for NCT06061263 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-sen University and is currently Recruitment Completed. The study focuses on Esophageal Cancer. Target enrollment is 96 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Yat-sen University
Timeline & Enrollment
N/A
May 01, 2022
Dec 01, 2023
Primary Outcome
recurrence-free survival
Summary
It has been reported that patients with esophageal squamous cell carcinoma who achieved
 pathological complete response (PCR) to neoadjuvant chemoradiotherapy have better survival
 than those with non-PCR. Howeve, there is still recurrent diseases developed in PCR patients
 after esophagectomy. Herein, we aimed to investgate the risk factors of recurrence in PCR
 patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06061263
Non-Device Trial